SpringerLink
Log in

Stable Engraftment after a Conditioning Regimen with Fludarabine and Melphalan for Bone Marrow Transplantation from an Unrelated Donor

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Graft failure and nonrelapse mortality (NRM) are major obstacles after the first unrelated-donor bone marrow transplantation (UD-BMT) with reduced-intensity conditioning. We evaluated UD-BMT with fludarabine (5 × 25 mg/m2) and melphalan (2 × 90 mg/m2) treatment combined with short-term methotrexate and tacrolimus (n = 20) or cyclosporine (n = 2) therapy for 22 patients with hematologic malignancies who were ineligible for conventional conditioning. Only 9 patients were in remission at transplantation. Seventeen patients underwent HLA-matched or DRB1 allele—mismatched transplantation, and 5 patients underwent HLA-A allele—mismatched or serologically HLA-DR—mismatched transplantation. Regimen-related toxicities were tolerable, although transient oral mucositis, hepatobiliary enzyme elevation, and diarrhea were observed frequently. All evaluable patients achieved sustained neutrophil engraftment, and all patients tested showed complete donor chimerism on day 28. With a median follow-up of 16 months, NRM and overall survival rates at 1 year were 19% and 81%, respectively, among the patients who underwent HLA-matched or DRB1 allele-mismatched transplantation. Acute graft-versus-host disease (GVHD) of grades II to IV occurred in 26% of the patients. The cumulative incidence of chronic GVHD was 44%. Despite the small number of patients and the short follow-up period, this reduced-intensity regimen enabled satisfactory engraftment and achievement of rapid complete donor chimerism with tolerable toxicities in the patients, including those who underwent HLA-mismatched UD-BMT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sasazuki T, Juji T, Morishima Y, et al, for the Japan Marrow Donor Program. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177–1185.

    Article  PubMed  CAS  Google Scholar 

  2. Kodera Y, Morishima Y, Kato S, et al. Analysis of 500 bone marrowtransplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant. 1999;24:995–1003.

    Article  PubMed  CAS  Google Scholar 

  3. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–4206.

    Article  CAS  PubMed  Google Scholar 

  4. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943–1951.

    Article  PubMed  CAS  Google Scholar 

  5. Woolfrey AE, Anasetti C, Storer B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002;99:2002–2008.

    Article  PubMed  CAS  Google Scholar 

  6. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968.

    Article  PubMed  CAS  Google Scholar 

  7. Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000;96:4096–4102.

    PubMed  CAS  Google Scholar 

  8. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmye-loablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030.

    Article  PubMed  CAS  Google Scholar 

  9. Baron F, Maris MB, Storer BE, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005;11:272–279.

    Article  PubMed  Google Scholar 

  10. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637.

    Article  PubMed  CAS  Google Scholar 

  11. Bornhauser M, Thiede C, Platzbecker U, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res. 2001;7:2254–2262.

    CAS  PubMed  Google Scholar 

  12. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052–3059.

    Article  PubMed  CAS  Google Scholar 

  13. Rodriguez R, Parker P, Nademanee A, et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant. 2004;33:1123–1129.

    Article  PubMed  CAS  Google Scholar 

  14. Yanada M, Emi N, Naoe T, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant. 2004;34:331–337.

    Article  PubMed  CAS  Google Scholar 

  15. Barker JN, Davies SM, DeFor TE, et al. Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults. Br J Haematol. 2002;118:101–107.

    Article  PubMed  CAS  Google Scholar 

  16. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:181–185.

    Article  PubMed  CAS  Google Scholar 

  17. Gleissner B, Gokbuget N, Bartram CR, et al, and the German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed poly-merase chain reaction analysis. Blood. 2002;99:1536–1543.

    Article  PubMed  CAS  Google Scholar 

  18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant.1995;15:825–828.

    PubMed  CAS  Google Scholar 

  19. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259.

    PubMed  CAS  Google Scholar 

  20. Hurley CK, Baxter-Lowe LA, Logan B, et al. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant. 2003;9:610–615.

    Article  PubMed  Google Scholar 

  21. Sakiyama M, Kami M, Hori A, et al. Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0. Bone Marrow Transplant. 2004;34:787–794.

    Article  PubMed  CAS  Google Scholar 

  22. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13–47.

    Article  PubMed  CAS  Google Scholar 

  23. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102:3829–3836.

    Article  PubMed  CAS  Google Scholar 

  24. Keil F, Prinz E, Moser K, et al. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allo-geneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation. 2003;76:230–236.

    Article  PubMed  CAS  Google Scholar 

  25. Bishop MR, Hou JW, Wilson WH, et al. Establishment of early donor engraftment after reduced-intensity allogeneic hemato-poietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant. 2003;9:162–169.

    Article  PubMed  Google Scholar 

  26. Kusumi E, Kami M, Yuji K, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant. 2004;33:697–702.

    Article  PubMed  CAS  Google Scholar 

  27. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation. 2004;78:1014–1020.

    Article  PubMed  Google Scholar 

  28. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786–1799.

    Article  PubMed  CAS  Google Scholar 

  29. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol. 2005;130:394–403.

    Article  PubMed  Google Scholar 

  30. Chakrabarti S, Hale G, Waldmann H. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? Transplant Proc. 2004;36:1225–1227.

    Article  PubMed  CAS  Google Scholar 

  31. Popat U, Carrum G, May R, et al. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005;35:1127–1132.

    Article  PubMed  CAS  Google Scholar 

  32. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004;78:122–127.

    PubMed  CAS  Google Scholar 

  33. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol. 2003;21:506–513.

    Article  PubMed  Google Scholar 

  34. Schleuning M, Gunther W, Tischer J, Ledderose G, Kolb HJ. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant. 2003;32:243–250.

    Article  PubMed  CAS  Google Scholar 

  35. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Japan

    Yoshihiro Inamoto, Taku Oba, Koichi Miyamura, Akane Tsujimura, Yachiyo Kuwatsuka, Masahiro Tokunaga, Masanobu Kasai & Yoshihisa Kodera

  2. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan

    Seitaro Terakura, Makoto Murata & Tomoki Naoe

Authors
  1. Yoshihiro Inamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taku Oba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koichi Miyamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seitaro Terakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akane Tsujimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yachiyo Kuwatsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiro Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masanobu Kasai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Makoto Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tomoki Naoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshihisa Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Inamoto.

About this article

Cite this article

Inamoto, Y., Oba, T., Miyamura, K. et al. Stable Engraftment after a Conditioning Regimen with Fludarabine and Melphalan for Bone Marrow Transplantation from an Unrelated Donor. Int J Hematol 83, 356–362 (2006). https://doi.org/10.1532/IJH97.05168

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.05168

Key words

Search

Navigation